Discovery of a New Boron-Containing Antifungal Agent, 5-Fluoro-1,3-dihydro-1-hydroxy-2,1- benzoxaborole (AN2690), for the Potential Treatment of Onychomycosis
- 27 June 2006
- journal article
- letter
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 49 (15), 4447-4450
- https://doi.org/10.1021/jm0603724
Abstract
A structure−activity relationship investigation for a more efficacious therapy to treat onychomycosis, a fungal infection of the toe and fingernails, led to the discovery of a boron-containing small molecule, 5-fluoro-1,3-dihydro-1-hydroxy-2,1-benzoxaborole (AN2690), which is currently in clinical trials for onychomycosis topical treatment.Keywords
This publication has 8 references indexed in Scilit:
- Identification of Borinic Esters as Inhibitors of Bacterial Cell Growth and Bacterial Methyltransferases, CcrM and MenHJournal of Medicinal Chemistry, 2005
- Epidemiology, clinical presentation and diagnosis of onychomycosisBritish Journal of Dermatology, 2003
- Onychomycosis in clinical practice: factors contributing to recurrenceBritish Journal of Dermatology, 2003
- Treatment Failures and Relapses in Onychomycosis: A Stubborn Clinical ProblemDermatology, 2003
- A large-scale North American study of fungal isolates from nails: The frequency of onychomycosis, fungal distribution, and antifungal susceptibility patternsJournal of the American Academy of Dermatology, 2000
- New Syntheses of Substituted Pyridines via Bromine–Magnesium ExchangeTetrahedron, 2000
- Onychomycosis: current treatment and future challengesBritish Journal of Dermatology, 1999
- Diaminopyrimidines and Severe Cutaneous Adverse ReactionsArchives of Dermatology, 1997